*NOTE: This study is closed/manuscript in progress*

The aim of this study is to evaluate client perception of quality of life improvement in Labrador Retrievers with laryngeal paralysis (LP) given doxepin for one month compared to dogs given placebo.

Inclusion Criteria

Labrador Retrievers with clinical signs consistent with non-critical LP. To be evaluated for enrollment, dogs will have initial history and physical exam. If considered likely to have LP, dogs will have routine hematologic, biochemical, and thyroid evaluation.

Exclusion Criteria

• Unstable LP such that surgery is likely to be needed within the study period
• Serious co-morbidities that might affect laryngeal function or preclude completion of the study including untreated hypothyroidism, neoplasia, severe heart disease, severe renal or liver disease.
• History of urine retention, glaucoma or severe cardiac disease
• Administration of drugs known to potentiate serotonin syndrome including Monoamine oxidase inhibitors, cimetidine, meperidine, dextromethorphan, quinidine, serum serotonin reuptake inhibitors, and anticholinergic agents

Owner Incentives

Reduced initial exam charge. No charge for blood work, echolaryngography, neurologic evaluation, and study medication for enrolled dogs. The client is responsible for all other charges. A $100 account credit will be given at completion of study.

Contact

Jill Sammarco, BVSc, MRCVS, DACVS
RBVH Surgery Department (Tinton Falls)
(732) 747-3636

Eric N. Glass, MS, DVM, DACVIM (Neurology)
RBVH Neurology & Neurosurgery Department
(732) 747-3636

See All Clinical Studies